专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1997038113A1 POLYPEPTIDE OF HUMAN-ORIGIN HYALURONATE SYNTHETASE AND DNA ENCODING THE SAME 审中-公开
标题翻译：人源HYALURONATE SYNTHETASE的多肽和编码其的DNA
公开(公告)号：WO1997038113A1
公开(公告)日：1997-10-16
申请号：PCT/JP1997001111
申请日：1997-03-31
申请人： SEIKAGAKU CORPORATION , ITANO, Naoki , KIMATA, Koji
发明人： SEIKAGAKU CORPORATION
IPC分类号： C12N15/56
CPC分类号： C12N9/1051
摘要： A DNA encoding at least part of the polypeptide of a human-origin hyaluronate synthetase, in particular, a DNA encoding the whole or part of the amino acid sequence represented by SEQ ID NO:4. The polypeptide encoded by the above DNA may be one that has undergone the substitution, deletion or insertion of at least one amino acid residue that does not substantially damage the activity of synthesizing hyaluronic acid. The invention also provides the polypeptides of the human-origin hyalurate synthetase encoded by the DNA or parts thereof.
摘要翻译：编码人源化透明质酸合成酶的多肽的至少一部分的DNA，特别是编码SEQ ID NO：4所示的全部或部分氨基酸序列的DNA。由上述DNA编码的多肽可以是经历至少一个氨基酸残基的取代，缺失或插入的多肽，其不会显着损伤合成透明质酸的活性。本发明还提供了由DNA或其部分编码的人源化的透明质酸合成酶的多肽。

2. 发明申请

WO1998029125A1 REMEDIES FOR BLADDER DISORDERS 审中-公开
标题翻译：补救障碍
公开(公告)号：WO1998029125A1
公开(公告)日：1998-07-09
申请号：PCT/JP1997004894
申请日：1997-12-26
申请人： SEIKAGAKU CORPORATION , TAKAHASHI, Katsuya , MIYAUCHI, Satoshi
发明人： SEIKAGAKU CORPORATION
IPC分类号： A61K31/725
CPC分类号： A61K31/715 , A61K9/0034
摘要： Remedies for bladder disorders capable of extending the vesical mucosal epithelium and/or repairing the vesical mucosa and thus exerting excellent therapeutic effects on bladder disorders, in particular, non-bacterial intractable bladder disorders. These drugs are prepared by compounding remedies for bladder disorders with hyaluronic acid and/or pharmaceutically acceptable salts thereof, preferably those having the properties as will be specified hereinbelow, in such an amount as to be efficacious in extending the vesical mucosal epithelium and/or repairing the vesical mucosa, preferably from 0.2 to 0.6 % by weight based on the whole preparation: (A) containing not more than 0.03 EU (endotoxin unit)/10 mg of endotoxins; (B) containing not more than 0.01 % of sulfur when determined by coulometric titration; (C) containing not more than 20 ppm of iron; (D) containing not more than 0.1 % of proteins; and (E) having a weight-average molecular weight of at least about 500,000.
摘要翻译：能够扩展膀胱粘膜上皮和/或修复膀胱粘膜的膀胱功能障碍，从而对膀胱疾病，特别是非细菌难治性膀胱疾病起到优异的治疗作用。这些药物通过将透明质酸和/或其药学上可接受的盐，优选具有下文将要指定的性质的药物配合用于膀胱疾病的补救剂，其量可以有效延长膀胱粘膜上皮和/或修复（A）含有不超过0.03欧姆（内毒素单位）/ 10mg内毒素的组合物，优选为0.2〜0.6重量％（B）当通过库仑滴定测定时，含有不超过0.01％的硫; （C）含有不超过20ppm的铁; （D）含有不超过0.1％的蛋白质; 和（E）的重均分子量为至少约500,000。

3. 发明申请

WO1995005177A1 REMEDY FOR NERVOUS DISEASES 审中-公开
标题翻译：补救神经疾病
公开(公告)号：WO1995005177A1
公开(公告)日：1995-02-23
申请号：PCT/JP1994001342
申请日：1994-08-12
申请人： SEIKAGAKU CORPORATION , INOKUCHI, Jinichi , KURODA, Yoichiro , MURAMOTO, Kazuyo , YAMADA, Haruki , USUKI, Seigou
发明人： SEIKAGAKU CORPORATION
IPC分类号： A61K31/535
CPC分类号： C07D295/13 , A61K31/5375 , C07D295/125 , Y10S514/937
摘要： A remedy for nervous diseases caused by peripheral or central nervous disorder containing a 2-acylaminopropanol derivative represented by general formula (I) or a pharmaceutically acceptable salt thereof as the active ingredient, wherein R represents alkyl, or phenyl or cyclohexyl both of which may be substituted by one to three same or different substituents selected from the group consisting of alkyl, alkoxy, hydroxy and nitro. It can be used for treating various central and peripheral nervous diseases by inducing biosynthesis of endogenous glycosphingolipids, especially a ganglioside, to thereby accelerate axon extension and synapse formation.
摘要翻译：由通式（I）表示的2-酰基氨基丙醇衍生物或其药学上可接受的盐作为活性成分的外周或中枢神经紊乱引起的神经疾病的补救措施，其中R 1表示烷基或苯基或环己基其可以被一至三个相同或不同的选自烷基，烷氧基，羟基和硝基的取代基取代。通过诱导内源性糖鞘脂，特别是神经节苷脂的生物合成，可以用于治疗各种中枢和周围神经疾病，从而加速轴突延伸和突触形成。

4. 发明申请

WO1993021193A1 PLATINUM COMPLEX AND ANTINEOPLASTIC AGENT 审中-公开
标题翻译：铂复合物和抗肿瘤药物
公开(公告)号：WO1993021193A1
公开(公告)日：1993-10-28
申请号：PCT/JP1993000483
申请日：1993-04-15
申请人： SEIKAGAKU CORPORATION , SAKURAI, Katsukiyo , MAEDA, Mitsuaki
发明人： SEIKAGAKU CORPORATION
IPC分类号： C07F15/00
CPC分类号： A61K31/715 , A61K31/28 , A61K33/24 , A61K45/06 , A61K47/61 , C08B37/0069 , A61K2300/00
摘要： A platinum complex comprising a cycloalkanediamine platinum (II) and, coordinated thereto, the carboxyl and/or sulfate groups of chondroitin sulfate mainly comprising the 4-sulfate. It is electrophoretically uniform, contains at most 5 wt. % of platinum, and has a solubility of 10 mg/ml or above in water at 20 DEG C. This complex is remarkably improved in water solubility and antineoplastic activity and has a high organ selectivity for the liver and the like.
摘要翻译：包含环烷二胺铂（II）并与其配位的主要包含4-硫酸盐的硫酸软骨素的羧基和/或硫酸根的铂络合物。电泳均匀，最多含5wt。％的铂，并且在20℃下在水中的溶解度为10mg / ml以上。该配合物在水溶性和抗肿瘤活性方面显着提高，并且对肝脏等具有高的器官选择性。

5. 发明申请

WO1996016166A1 NOVEL KERATAN SULFATE HYDROLASE 审中-公开
标题翻译：新的卡尔坦硫酸盐水解剂
公开(公告)号：WO1996016166A1
公开(公告)日：1996-05-30
申请号：PCT/JP1995002385
申请日：1995-11-22
申请人： SEIKAGAKU CORPORATION , MORIKAWA, Kiyoshi , MARUYAMA, Hiroshi , ISOMURA, Takako , SUZUKI, Kiyoshi , TATEBAYASHI, Sadao
发明人： SEIKAGAKU CORPORATION
IPC分类号： C12N09/36
CPC分类号： C12Y302/01096 , C12N9/2462
摘要： A novel keratan sulfate hydrolase, endo- beta -N-acetylglucosaminidase, produced by a novel strain Bacillus circulans KsT202.
摘要翻译：一种新型硫酸角质素水解酶，内切-β-N-乙酰葡糖胺酶，由新型菌株环状芽孢杆菌KsT202产生。

6. 发明申请

WO1995034530A1 2-ACYLAMINOPROPANOL COMPOUND AND MEDICINAL COMPOSITION 审中-公开
标题翻译： 2-乙酰氨基酚类化合物和药物组合物
公开(公告)号：WO1995034530A1
公开(公告)日：1995-12-21
申请号：PCT/JP1995001143
申请日：1995-06-07
申请人： SEIKAGAKU CORPORATION , INOKUCHI, Jinichi , JINBO, Masayuki , NAGAI, Takayuki , YAMADA, Haruki
发明人： SEIKAGAKU CORPORATION
IPC分类号： C07C233/43
CPC分类号： C07D295/185 , C07C233/36 , C07C2601/14 , C07D207/12 , C07D211/22 , C07D211/46 , C07D295/125 , Y10S977/798 , Y10S977/904 , Y10S977/915
摘要： A 2-acylaminopropanol compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, and a medicinal composition containing the same as the active ingredient and being efficacious as an antiviral agent and a remedy for nervous diseases, wherein R represents phenyl which may be substituted by one to three same or different substituents selected from among alkyl, alkoxy, hydroxy, hydroxyalkyl and nitro; R represents a group represented by any of general formulae (II) through (VI) wherein, R , R , R , R , R , R , R , m and p are each as defined in the specification; R represents hydrogen or hydroxy; and n represents an integer of 3 to 15.
摘要翻译：由通式（I）表示的2-酰基氨基丙醇化合物或其药学上可接受的盐，和含有该活性成分的药物组合物，作为抗病毒剂和神经病的药物有效，其中R 1表示可以被一至三个相同或不同的选自烷基，烷氧基，羟基，羟烷基和硝基的取代基取代的苯基; R 2表示由通式（II）至（VI）中的任一个表示的基团，其中R 3，R 4，R 5，R 6，R 7，R 8 >，R 9，m和p各自如说明书中所定义; R 11表示氢或羟基; n表示3〜15的整数。

7. 发明申请

WO1995025287A1 MATERIAL TO BE WORN ON THE EYEBALL 审中-公开
标题翻译：在眼睛上的材料
公开(公告)号：WO1995025287A1
公开(公告)日：1995-09-21
申请号：PCT/JP1995000419
申请日：1995-03-14
申请人： SEIKAGAKU CORPORATION , MATSUDA, Takehisa , NAKAO, Hiroshi
发明人： SEIKAGAKU CORPORATION
IPC分类号： G02B01/04
CPC分类号： A61K9/0051 , G02B1/043 , C08L5/00
摘要： The present invention provides semi-spherical materials to be worn on the eyeball, such as contact lenses for visual acuity correction or medical treatment use, cornea protecting materials, controlled drug release contact lenses and the like, which comprise, as a main component, a glycosaminoglycan existing in the living body as an extracellular matrix component of connective tissues and satisfy various requirements such as a dimensional stability, transparency, surface water wettability, tissue compatibility, oxygen permeability and the like. In other words, the material to be worn on the eyeball has a shape of semi-spherical surface compatible in shape with the mammalian eyeball and has biological and surface-physical compatibilities with ophthalmic tissues and comprises, as a main component, a substantially transparent photocured crosslinked-glycosaminoglycan obtained by allowing photoreactive groups covalently bonded to a glycosaminoglycan to crosslink mutually by photoirradiation.
摘要翻译：本发明提供了要戴在眼球上的半球形材料，例如用于视力矫正或医疗用途的隐形眼镜，角膜保护材料，受控药物释放隐形眼镜等，其以主要组分为主要成分，存在于生物体中的糖胺聚糖作为结缔组织的细胞外基质成分，满足尺寸稳定性，透明性，表面水润湿性，组织相容性，透氧性等各种要求。换句话说，穿戴在眼球上的材料具有与哺乳动物眼球相容的半球形表面形状，并且与眼组织具有生物学和表面 - 物理的相容性，并且包括作为主要成分的基本上透明的光固化通过使与光聚合相互作用的光活性基团与糖胺聚糖相互交联而获得的交联糖胺聚糖。

8. 发明申请

WO1998016825A1 METHOD FOR ASSAYING AGALACTO-IgG AND ASSAY KITS, POLYPEPTIDES OF LECTINS, AND DNAS ENCODING THE SAME 审中-公开
标题翻译：用于测定AGALACTO-IgG和测定试剂盒的方法，LECTINS的多肽和编码其的DNA
公开(公告)号：WO1998016825A1
公开(公告)日：1998-04-23
申请号：PCT/JP1997003723
申请日：1997-10-15
申请人： SEIKAGAKU CORPORATION , ICHO, Tateo , MIYAURA, Shuichi , ASANO, Yasushi , AKIYOSHI, Junko
发明人： SEIKAGAKU CORPORATION
IPC分类号： G01N33/53
CPC分类号： C07K14/4726 , C07K14/42 , C07K2319/00 , G01N33/564 , G01N33/6854 , G01N2333/42 , G01N2800/102
摘要： A method for assaying an agalacto-IgG in specimens which involves the step of reacting the specimen with a lectin adherent onto a solid phase and forming a complex of the agalacto-IgG with the lectin adherent onto the solid phase; a method for detecting rheumatism with the use of this assay method; kits for detecting the agalacto-IgG and kits for diagnosing rheumatism; and polypeptides of lectins usable in these methods and DNAs encoding the same.
摘要翻译：一种用于测定样品中的乳酸 - IgG的方法，其包括使样品与凝集素粘附在固相上并使乳糖 - IgG与凝集素粘附在固相上的复合物反应的步骤; 使用该测定方法检测风湿病的方法; 用于检测agalacto-IgG的试剂盒和用于诊断风湿病的试剂盒; 和可用于这些方法的凝集素的多肽和编码它们的DNA。

9. 发明申请

WO1997011096A1 ANTI-INFLAMMATORY AGENT 审中-公开
标题翻译：抗炎剂
公开(公告)号：WO1997011096A1
公开(公告)日：1997-03-27
申请号：PCT/JP1996002706
申请日：1996-09-19
申请人： SEIKAGAKU CORPORATION , KYOGASHIMA, Mamoru , ASARI, Akira
发明人： SEIKAGAKU CORPORATION
IPC分类号： C08B37/00
CPC分类号： A61K38/13 , A61K31/445 , A61K31/505 , A61K31/52 , A61K31/57 , A61K31/675 , A61K31/70 , A61K31/715 , A61K31/726 , A61K31/727 , A61K31/737 , A61K45/06 , Y10S514/886 , A61K2300/00
摘要： An anti-inflammatory agent efficacious in treating protracted inflammation or inflammation in which the immune mechanism participates. The agent comprises as the active ingredient dermatan sulfate or a pharmacologically acceptable salt thereof. The agent is usable in preventing or treating inflammation in association with glomerulonephritis, collagen disease, multiple sclerosis, intractable angiitis, immunopathy or autoimmune diseases. When used together with immunosuppressants (adrenocortical hormone, etc.), the agent largely enhances the effects achieved by the immunosuppressants, which makes it possible to reduce the dose of the immunosuppressants. It is orally, intramuscularly, intraarterially or intravascularly administered in a dose of from 50 to 3,000 mg/day.
摘要翻译：抗炎剂有效治疗免疫机制参与的持续炎症或炎症。该药剂包含作为活性成分的硫酸皮肤素或其药理学上可接受的盐。该药剂可用于预防或治疗与肾小球性肾炎，胶原病，多发性硬化，顽固性血管炎，免疫病或自身免疫性疾病有关的炎症。当与免疫抑制剂（肾上腺皮质激素等）一起使用时，该试剂大大增强了免疫抑制剂实现的效果，这使得可以减少免疫抑制剂的剂量。口服，肌肉内，动脉内或血管内给药剂量为50至3,000mg /天。

10. 发明申请

WO1996006858A1 (1}3)-'beta'-D-GLUCAN-BINDING PROTEIN, ANTIBODY THAT RECOGNIZES THE PROTEIN, AND USE OF THE PROTEIN AND ANTIBODY 审中-公开
标题翻译：（1）3）-β-D-葡萄糖结合蛋白，识别蛋白质的抗体以及蛋白质和抗体的使用
公开(公告)号：WO1996006858A1
公开(公告)日：1996-03-07
申请号：PCT/JP1995001735
申请日：1995-08-31
申请人： SEIKAGAKU CORPORATION , TAMURA, Hiroshi , TANAKA, Shigenori
发明人： SEIKAGAKU CORPORATION
IPC分类号： C07K14/435
CPC分类号： G01N33/579 , C07K14/43509 , C07K16/18 , G01N2400/24 , Y10S435/962 , Y10S530/857
摘要： A (1}3)- beta -D-glucan-binding protein that can be obtained by subjecting limulus hemocyte extract to affinity chromatography and gel filtration and has a molecular weight of about 580 kDa (according to gel filtration under nonreductive conditions) or about 170 kDa (according to SDS-PAGE under reductive conditions) or a variant thereof; and antibody that recognizes selectively the protein and the variant; a method of detecting (1}3)- beta -D-glucan contained in a specimen by using the protein and the antibody; and a method of removing (1}3)-D-glucan contained in a sample by using a carrier containing the protein bound thereto. The protein and the antibody can thus be used for detecting an endotoxin, (1}3)- beta -D-glucan, contained in a specimen or sample and removing (1}3)- beta -D-glucan therefrom.
摘要翻译： A（1）3）-β-D-葡聚糖结合蛋白，其可以通过使鲎血细胞提取物进行亲和层析和凝胶过滤获得，并且具有约580kDa的分子量（根据在非还原条件下的凝胶过滤）或约 170kDa（根据还原条件下的SDS-PAGE）或其变体; 和选择性识别蛋白质和变体的抗体; 通过使用蛋白质和抗体检测样品中所含的（1）3）-β-D-葡聚糖的方法; 以及通过使用含有结合蛋白质的载体除去样品中所含的（1）3）-D-葡聚糖的方法。因此，蛋白质和抗体可用于检测样品或样品中所含的内毒素（1）3）-β-D-葡聚糖，并从其中除去（1）3）-β-D-葡聚糖。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式